Litigation Details for Allergan, Inc. v. Mankind Pharma Ltd. (D. Del. 2023)
✉ Email this page to a colleague
Allergan, Inc. v. Mankind Pharma Ltd. (D. Del. 2023)
| Docket | ⤷ Sign Up | Date Filed | 2023-03-13 |
| Court | District Court, D. Delaware | Date Terminated | 2024-10-29 |
| Cause | 35:271 Patent Infringement | Assigned To | John F. Murphy |
| Jury Demand | None | Referred To | |
| Patents | 7,851,504; 8,338,479 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Allergan, Inc. v. Mankind Pharma Ltd.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Allergan, Inc. v. Mankind Pharma Ltd. (D. Del. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2024-07-03 | 110 | Strike | invalidity contentions concerning U.S. Patent No. 7,851,504 (the “’504 patent”). On September 27, 2023, Mankind…invalidity contentions concerning U.S. Patent No. 7,851,504 are STRICKEN. …the validity of the ’504 patent, that “all discovery pertinent only to patent validity … is not relevant… 2023 29 October 2024 1:23-cv-00272 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2024-07-17 | 123 | Brief - Answering Brief in Opposition | prolong the life of an invalid patent, U.S. Patent No. 7,851,504 (the “’504 patent”) and prevent generic competition…permitted to challenge the patent for DP. Maintaining the suit of an invalid patent does not 1 In the meet…Mankind’s invalidity argument based on double patenting (“DP”). By precluding this argument, Plaintiffs… to include an affirmative defense of double patenting. (D.I. 92) (“Motion to Vacate”). Mankind will …litigation even if a change to DP law renders the ’504 patent invalid. But if the expected change in DP is announced | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
